Triosephosphate isomerase as a therapeutic target against trichomoniasis

2021 ◽  
Vol 246 ◽  
pp. 111413
Author(s):  
Claudia G. Benítez-Cardoza ◽  
Luis G. Brieba ◽  
Rossana Arroyo ◽  
Arturo Rojo-Domínguez ◽  
José L. Vique-Sánchez
2021 ◽  
Vol 12 (4) ◽  
pp. 5672-5697

Tuberculosis (TB) is possibly the most prevalent infectious disease in the world, reports from the World Health Organization (WHO) indicate that TB is one of the top 10 causes of death and an estimated 10 million people worldwide, in addition, there are increasing the TB resistant to conventional antibiotics, multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Lastly, TB has become more important and requires more attention since it has been proposed as a risk factor for the severity of COVID-19. Therefore, the need to develop new anti-TB drugs. In this study, we propose to use the glycolytic enzyme triosephosphate isomerase from Mycobacterium tuberculosis (MtTIM) as a therapeutic target against TB. The triosephosphate isomerase (TIM) is a target used in different proposals to develop new drugs against different organisms. The MtTIM is an extremely attractive drug target due to the characteristics of its amino acids sequence. In addition, it has been determined that this enzyme (MtTIM) is necessary for the viability of in vitro and in vivo cultures of Mycobacterium tuberculosis. In this way, using the MtTIM as a therapeutic target, we propose potential compounds against MtTIM by molecular docking.


2019 ◽  
Vol 476 (21) ◽  
pp. 3333-3353 ◽  
Author(s):  
Malti Yadav ◽  
Kamalendu Pal ◽  
Udayaditya Sen

Cyclic dinucleotides (CDNs) have emerged as the central molecules that aid bacteria to adapt and thrive in changing environmental conditions. Therefore, tight regulation of intracellular CDN concentration by counteracting the action of dinucleotide cyclases and phosphodiesterases (PDEs) is critical. Here, we demonstrate that a putative stand-alone EAL domain PDE from Vibrio cholerae (VcEAL) is capable to degrade both the second messenger c-di-GMP and hybrid 3′3′-cyclic GMP–AMP (cGAMP). To unveil their degradation mechanism, we have determined high-resolution crystal structures of VcEAL with Ca2+, c-di-GMP-Ca2+, 5′-pGpG-Ca2+ and cGAMP-Ca2+, the latter provides the first structural basis of cGAMP hydrolysis. Structural studies reveal a typical triosephosphate isomerase barrel-fold with substrate c-di-GMP/cGAMP bound in an extended conformation. Highly conserved residues specifically bind the guanine base of c-di-GMP/cGAMP in the G2 site while the semi-conserved nature of residues at the G1 site could act as a specificity determinant. Two metal ions, co-ordinated with six stubbornly conserved residues and two non-bridging scissile phosphate oxygens of c-di-GMP/cGAMP, activate a water molecule for an in-line attack on the phosphodiester bond, supporting two-metal ion-based catalytic mechanism. PDE activity and biofilm assays of several prudently designed mutants collectively demonstrate that VcEAL active site is charge and size optimized. Intriguingly, in VcEAL-5′-pGpG-Ca2+ structure, β5–α5 loop adopts a novel conformation that along with conserved E131 creates a new metal-binding site. This novel conformation along with several subtle changes in the active site designate VcEAL-5′-pGpG-Ca2+ structure quite different from other 5′-pGpG bound structures reported earlier.


2003 ◽  
Vol 70 ◽  
pp. 213-220 ◽  
Author(s):  
Gerald Koelsch ◽  
Robert T. Turner ◽  
Lin Hong ◽  
Arun K. Ghosh ◽  
Jordan Tang

Mempasin 2, a ϐ-secretase, is the membrane-anchored aspartic protease that initiates the cleavage of amyloid precursor protein leading to the production of ϐ-amyloid and the onset of Alzheimer's disease. Thus memapsin 2 is a major therapeutic target for the development of inhibitor drugs for the disease. Many biochemical tools, such as the specificity and crystal structure, have been established and have led to the design of potent and relatively small transition-state inhibitors. Although developing a clinically viable mempasin 2 inhibitor remains challenging, progress to date renders hope that memapsin 2 inhibitors may ultimately be useful for therapeutic reduction of ϐ-amyloid.


2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
A Meinel ◽  
C Leo ◽  
G Zimmermann ◽  
H Alexander ◽  
LC Horn

2012 ◽  
Vol 224 (06) ◽  
Author(s):  
H Cin ◽  
J Gronych ◽  
A Korshunov ◽  
DTW Jones ◽  
D Milford ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document